Loading clinical trials...
Loading clinical trials...
Immune Reconstitution With Blinatumomab Expanded T-cells (BET) After First-line Treatment With Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab in CD20+ Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia: a Phase I Study
Conditions
Interventions
Blinatumomab Expanded T-cells (BET)
Locations
1
Italy
ASST - Papa Giovanni XXIII
Bergamo, Italy
Start Date
December 17, 2018
Primary Completion Date
November 11, 2021
Completion Date
November 1, 2022
Last Updated
December 23, 2021
Lead Sponsor
A.O. Ospedale Papa Giovanni XXIII
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions